FDA Approves Biohaven’s Nurtec for Acute Treatment of Migraines

Biohaven Pharmaceuticals received FDA approval for Nurtec ODT (rimegepant) for the acute treatment of migraine in adults.

The approval was based on the results of a phase 3 clinical trial in which Nurtec ODT achieved statistically significant improvement in freedom from pain and from the most bothersome symptom at two hours post dose compared to a placebo.

Nurtec ODT is the company’s first FDA-approved product.